BusinessLabcorp Agrees to Buy BioReference Assets for $722 MillionBy Helena WardOct 15, 2026, 2:05 PM UTC
BusinessCocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C VirusBy Nasdaq OMXApr 3, 2018, 12:01 PM UTC
